Evidence map›Paper›PMID 35369034›Full record

ArticleInternational journal of nanomedicine2022

Fluorescent Imaging-Guided Chemo- and Photodynamic Therapy of Hepatocellular Carcinoma with HCPT@NMOFs-RGD Nanocomposites.

Yue Shang, Hui Zhang, Yajia Cheng, Peipei Cao, Jianlin Cui, Xuebo Yin, Saijun Fan, Yuhao Li

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yue Shang *Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
Hui Zhang *Shanghai Institute of Quality Inspection and Technical Research, Shanghai, People's Republic of China.
Yajia ChengDepartment of Pathology, Nankai University School of Medicine, Tianjin, People's Republic of China.
Peipei CaoDepartment of Pathology, Nankai University School of Medicine, Tianjin, People's Republic of China.
Jianlin CuiDepartment of Pathology, Nankai University School of Medicine, Tianjin, People's Republic of China.
Xuebo YinCollege of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, People's Republic of China.
Saijun FanInstitute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
Yuhao LiBeijing Geriatric Medical Research Center, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China.ORCID 0000-0003-2022-9526
Nankai University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNCapital Medical University · CNShanghai Institute of Quality Inspection and Technical Research · CNShanghai University of Engineering Science · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC), arising from hepatocytes, is the most common primary liver cancer. It is urgent to develop novel therapeutic approaches to improve the grim prognosis of advanced HCC. 10-hydroxycamptothecin (HCPT) has good antitumor activity in cells; however, its hydrophobicity limits its application in the chemotherapy of HCC. Recently, nanoscale porphyrin metal-organic frameworks have been used as drug carriers due to their low biotoxicity and photodynamic properties. Methods: Nanoscale zirconium porphyrin metal-organic frameworks (NMOFs) were coated with arginine-glycine-aspartic acid (RGD) peptide to prepare NMOFs-RGD first. The HepG2 cell line, zebrafish embryos and larvae were used to test the biotoxicity and fluorescence imaging capability of NMOFs-RGD both in vitro and in vivo. Then, NMOFs were used as the skeleton, HCPT was assembled into the pores of NMOFs, while RGD peptide was wrapped around to synthesize a novel kind of nanocomposites, HCPT@NMOFs-RGD. The tissue distribution and chemo- and photodynamic therapeutic effects of HCPT@NMOFs-RGD were evaluated in a doxycycline-induced zebrafish HCC model and xenograft mouse model. Results: NMOFs-RGD had low biotoxicity, good biocompatibility and excellent imaging capability. In HCC-bearing zebrafish, HCPT@NMOFs-RGD were specifically enriched in the tumor by binding specifically to integrin α Conclusion: The nanocomposites HCPT@NMOFs-RGD accomplish tumor targeting and play synergistic chemo- and photodynamic therapeutic effects on HCC, offering a novel imaging-guided drug delivery and theranostic platform.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNanocompositesPhotochemotherapyAnimalsCamptothecinHumansMiceOligopeptidesZebrafisharginyl-glycyl-aspartic acidCamptothecinhomocamptothecinOligopeptides10-hydroxycamptothecinchemotherapyhepatocellular carcinomaphotodynamic therapyzirconium porphyrin metal-organic frameworks

Identifiers

PMID35369034
PMCPMC8964448
OpenAlexW4220934074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.